Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-29T09:49:44.349Z Has data issue: false hasContentIssue false
  • English
  • Français

Regulatory Perspectives: One Academic Viewpoint From the United States

Published online by Cambridge University Press:  10 January 2005

Peter Whitehouse
Peter Whitehouse
Affiliation:
Neurology, Neuroscience and Psychiatry, Case Western Reserve University, Cleveland, Ohio, US
Get access Rights & Permissions [Opens in a new window]

Abstract

The development of new drugs to treat vascular dementia and other conditions in which cognitive impairment is due at least in part to vascular pathology will require future interaction among academic, industry, and government regulatory clinicians and scientists. This article offers the author's perspective on the positive involvement of the Food and Drug Administration in development of conceptual frameworks and practical approaches to treatment of conditions characterized by vascular burden of the brain.

Keywords

Vascular dementiaregulatoryinternationaldrug development
Type
REGULATORY ISSUES: ACADEMIC VIEWPOINTS
Information
International Psychogeriatrics , Volume 15 , Issue S1 , July 2003 , pp. 277 - 281
Copyright
© 2003 International Psychogeriatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)